XRTX XORTX Therapeutics
- 2.4999
- +0.1499+6.38%
- 2.5000
- +0.0001+0.00%
XORTX Therapeutics News
XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
XORTX Therapeutics | 20-F: Registration statement / Annual report / Transition report
XORTX Therapeutics | NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 424B5: Prospectus
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
